Suit-Fong Chan

Ms. Suit-Fong Chan

MiRXES Pte Ltd, Singapore, Central Singapore, Singapore
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2007 in Hepatology
Verified
Journal Article
Open access
PDF file
CCChun-Jung Chang
Chun-Jung Chang
YCYi-Hsiang Chen
Yi-Hsiang Chen
KHKAI-WEN HUANG
KAI-WEN HUANG
HCHao-Wei Cheng
Hao-Wei Cheng
SCSuit-Fong Chan
Suit-Fong Chan
LHLih-Hwa Hwang
Lih-Hwa Hwang
Immunotherapy is often effective only for small tumor burdens and, in many cases, is restricted to subcutaneous tumors. Here, we investigated the antitumor effects of combination therapy with GM-CSF and IL-12 on orthotopic liver tumors with intermediate or large tumor volumes, or on chemically-induced multifocal liver tumors in animals. Adenoviruses encoding GM-CSF or IL-12 were injected intratumorally to animals bearing transplanted tumors, or injected via intrahepatic artery in animals with primary multifocal liver tumors induced by diethylnitrosamine. Our results demonstrated that IL-12, but not GM-CSF, monotherapy displayed significant therapeutic effects, whereas combination therapy with both cytokines displayed synergistic antitumor effects not only on transplanted tumor models with intermediate or large tumor loads, but also on carcinogen-induced multifocal liver tumors. Effector cell analyses, revealed by in vivo cell subset depletion, flow cytometry analysis, and immunohistochemical staining of tumor infiltrates, indicated that NK cells were the prominent antitumor effectors for the IL-12–mediated antitumor activity, whereas CD8+ T cells, NKT cells, and macrophages were more important than NK cells in the combination therapy–mediated antitumor effects. Both IL-12 monotherapy and combination therapy could induce various types of effectors and high levels of IFN-γ; however, the latter induced much higher levels than the former, which may explain why combination therapy is superior to IL-12 monotherapy. Conclusion: Combination therapy with GM-CSF and IL-12 represents a promising immunotherapy strategy for treating orthotopic, widespread liver tumors. (Hepatology 2007;45:746–754.)

6 April 2023 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
SCSuit-Fong Chan
Suit-Fong Chan
HCHe Cheng
He Cheng
KGKaren Kai-Rui Goh
Karen Kai-Rui Goh
RZRuiyang Zou
Ruiyang Zou
As miRNAs emerge as potential circulating biomarkers for the diagnosis or prognosis of a wide variety of diseases, the quantification of miRNA necessitates careful preanalytic considerations and sample quality control becomes crucial. This study comprehensively analyzed the profiles of 356 miRNAs by quantitative RT-PCR in various blood sample types, with various processing protocols. The comprehensive analysis investigated the correlations of individual miRNAs with certain confounding factors. On the basis of these profiles, a panel of 7 miRNAs was established for the quality control of samples corresponding to hemolysis and platelet contamination. The panel was used to investigate the confounding impacts based on the size of the blood collection tube, the centrifugation protocol, post-freeze-thaw spinning, and whole blood storage. A standard dual-spin workflow for the processing of blood had been established for optimal sample quality. The real-time stability of 356 miRNAs was also investigated with demonstration of the temperature and time-induced miRNA degradation profile. Stability-related miRNAs were identified from real-time stability study and further incorporated into the quality control panel. This quality control panel enables the assessment of sample quality for more robust and reliable detection of circulating miRNAs.

1 July 2012 in Cancer Letters
Verified
Journal Article
Closed access
SCSuit-Fong Chan
Suit-Fong Chan
HWHao-Tien Wang
Hao-Tien Wang
KHKAI-WEN HUANG
KAI-WEN HUANG
PTPao-Ling Torng
Pao-Ling Torng
HLHsin-I Lee
Hsin-I Lee
LHLih-Hwa Hwang
Lih-Hwa Hwang

17 May 2026 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
JSJoji Samejima
Joji Samejima
LZLi Zhou
Li Zhou
TKToru Kimura
Toru Kimura
YJYu Jin
Yu Jin
YTYugo Tanaka
Yugo Tanaka
MTMasahiro Tsuboi
Masahiro Tsuboi
Lung cancer remains a leading cause of cancer-related mortality worldwide, underscoring the critical need for early detection to improve patient outcomes. This study aimed to develop and validate a plasma microRNA biomarker panel for the early detection of non-small cell lung cancer in a Japanese cohort. We enrolled 525 participants, comprising 261 LC cases and 264 non-LC controls, divided into optimization and validation cohorts. A 12-miRNA panel was optimized and further combined with CEA to enhance diagnostic performance. The miRNA-alone model demonstrated robust performance in both the optimization (AUC = 77.0%) and validation cohorts (AUC = 77.9%). Integration with CEA significantly improved accuracy, achieving AUCs of 86.2% in optimization and 84.9% in validation, with particularly high performance in late-stage cancers (AUC = 94.4%) and squamous cell carcinoma (AUC = 90.7%). Sensitivity and specificity thresholds were evaluated, enabling model customization for diverse clinical scenarios. These findings highlight the potential of the miRNA-CEA panel as a minimally invasive tool for early LC detection, especially in non-smoking populations.